Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01506570 · ClinicalTrials.gov registry record · Phase 1

Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine

A Phase 1 study of Dengue, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
Phase 1
Development phase
58
Enrollment target
3
Study locations

NCT01506570 is a Phase 1 study of Dengue that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 58 participants, below the 3,975-participant average among 9 other Dengue trials with a reported enrollment target (99% lower). The trial reports 3 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01506570, a Phase 1 study of Dengue, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
Phase 1
Development phase
58 participants
Enrollment target
3
Study locations

Study Summary

Dengue viruses can cause dengue fever and other serious health conditions, primarily affecting people living in tropical regions of the world. This study will evaluate the safety and immune responses to two formulations of a tetravalent dengue virus vaccine in healthy adults who have previously been infected with a dengue virus or other flavivirus or have previously received a flavivirus vaccine.

Conditions Studied

Dengue

Interventions

  • BIOLOGICAL Placebo
  • BIOLOGICAL TetraVax-DV Vaccine - Admixture TV003
  • BIOLOGICAL TetraVax-DV Vaccine - Admixture TV005

Study Locations (3)

Vermont

  • Fletcher Allen Health Care (FAHC), General Clinical Research Center (GCRC) - Burlington
  • University of Vermont Vaccine Testing Center - Burlington

Maryland

  • Center for Immunization Research, Johns Hopkins School of Public Health - Baltimore

Trial Details

FieldValue
Enrollment Target 58 participants
Start Date 2011-12
Est. Completion 2013-09
Phase Phase 1

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

2,006 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01506570

The ClinicalTrials.gov registry entry for NCT01506570 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,975-participant average among 9 other Dengue trials with a reported enrollment target (99% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Dengue appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT01506570 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Vermont, Maryland.

Frequently Asked Questions

What is clinical trial NCT01506570 about?

NCT01506570 is a clinical study titled "Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine". Dengue viruses can cause dengue fever and other serious health conditions, primarily affecting people living in tropical regions of the world. This study will evaluate the safety and immune responses to two formulations of a tetravalent dengue virus vaccine in healthy adults who have previously been...

What is the current status of trial NCT01506570?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 58 participants. The study started on 2011-12. Estimated completion is 2013-09.

What conditions does trial NCT01506570 study?

This clinical trial studies the following conditions: Dengue.

What interventions are being tested in trial NCT01506570?

The interventions under investigation include: Placebo (BIOLOGICAL), TetraVax-DV Vaccine - Admixture TV003 (BIOLOGICAL), TetraVax-DV Vaccine - Admixture TV005 (BIOLOGICAL).

Who is sponsoring clinical trial NCT01506570?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01506570 being conducted?

This trial has 3 study locations across Maryland, Vermont. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Dengue

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Dengue

All registered trials for this condition

Maryland

All trials with a study site in Maryland

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.